Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
National Institute for Clinical Excellence
Record ID 32002000347
English
Authors' objectives:
To provide guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia.
Authors' recommendations:
Guidance 1.1 Oral fludarabine is recommended as second line therapy for B-cell chronic lymphocytic leukaemia (CLL) for patients who have either failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy of either:
1.1.1. cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
1.1.2. cyclophosphamide, doxorubicin and prednisolone (CAP) or
1.1.3. cyclophosphamide, vincristine and prednisolone (CVP)
1.2 The oral formulation of fludarabine is preferred to the intravenous formulation on the basis of more favourable cost effectiveness. Intravenous fludarabine should only be used when oral fludarabine is contra-indicated.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=22177
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Drug Therapy
- Leukemia, Lymphocytic, Chronic, B-Cell
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.